In a major milestone for Pakistan’s pharmaceutical industry, Haleon Pakistan Limited, formerly GlaxoSmithKline Consumer Healthcare Pakistan Limited, has successfully exported Centrum—a leading multivitamin brand—from its Jamshoro manufacturing facility to Kenya.
Read More: AKU in Pakistan Honours Founder, 473 Graduates
The company shared this development in a notice to the Pakistan Stock Exchange (PSX), stating that the first consignment has been dispatched. “This marks the beginning of an exciting journey, further enhancing our export operations in 2025,” the notice read. Haleon emphasized that this expansion supports Pakistan’s economy and creates new growth opportunities in international markets.
The company also acknowledged the role of relevant authorities and the Special Investment Facilitation Council (SIFC) in facilitating this achievement.
Haleon Pakistan, a subsidiary of Haleon Netherlands B.V., is engaged in the manufacturing, marketing, and sale of consumer healthcare and over-the-counter health products. The company was incorporated in 2015 under the provisions of the Companies Act, 2017.
Pakistan’s pharmaceutical sector has been expanding its global footprint, with increasing exports to international markets. Last month, Citi Pharma Limited (CPHL) completed its first-ever export to the MENA region, valued at EUR 560,000, following its FDA accreditation.
This latest export by Haleon Pakistan highlights the growing international demand for locally manufactured pharmaceutical products, positioning Pakistan as a key player in the global healthcare industry.
